newsMr. Robert Rieveley reports
BIOTECH HOLDINGS REVENUES GROW COMPARED TO EARLIER QUARTERS
Sales of Biotech Holdings Ltd.'s Sucanon diabetes drug for the quarter ended March 31, 2007, were $150,761. This was an increase of $23,567 or about 18.5 per cent over the revenues of the quarter ending Dec. 31, 2006, and an increase of $122,526 or approximately 400 per cent over revenues of $28,235 in the year-earlier quarter ending March 31, 2006.
The quarter ended March 31, 2007, was the second consecutive quarter of sales growth. To support this growth, the company added an additional manager to its Mexico office in January, 2007.
All figures are subject to confirmation in the issuance of the company's audited annual financial statements, including the March 31, 2007, quarter, which are projected to be made available and filed to SEDAR in the company's second fiscal quarter, ending Sept. 30, 2007.